Clinical Trial Update: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) [Phase 3]

View source ↗

Summary

Phase 3 study comparing LOXO-305 (pirtobrutinib) with approved BTK inhibitors in mantle cell lymphoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Ibrutinib (ibrutinib)
• LOXO-305 (pirtobrutinib)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Lymphoma, Mantle-Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING